Victoria Stern

1 month ago | mdedge.com | Victoria Stern

Last month, the United States Food and Drug Administration (FDA) approved two new drugs and two biosimilars as well as halted commercialization for a hemophilia treatment. Here’s a deeper look of what happened last month. New Drugs1. The FDA has approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.) for adult and pediatric patients 2 years or older with neurofibromatosis type 1 and symptomatic plexiform neurofibromas that are not amenable to complete resection.

2 months ago | medscape.com | Victoria Stern |Sharon Worcester |M. Alexander Otto

Last month, the US Food and Drug Administration (FDA) approved two new drugs, expanded the indications for several other agents as well as a diagnostic test, and issued a clinical trial hold on a trial investigating a new immunotherapy agent. Here’s a snapshot of what happened in January. New Drugs1.

Jan 24, 2025 | medscape.com | Victoria Stern |M. Alexander Otto

This week, the Trump administration imposed a range of restrictions that impact the National Institutes of Health (NIH). These include sudden meeting cancellations, such as expert panels that review grant proposals, as well as a broader pause on external communications at the US Department of Health and Human Services (HHS), HHS travel bans, and a federal hiring freeze. Cancellations of NIH grant review panels, in particular, could affectcancer research grants and funding.

Dec 2, 2024 | medscape.com | M. Alexander Otto |Sharon Worcester |Victoria Stern

Last month, the US Food and Drug Administration (FDA) approved three new drugs, changed the indication for one, lifted a clinical trial hold, and began a probe into blood cancer risk from bluebird’s gene therapy, among other things. Here’s a snapshot of what happened in November. New drugs1. The FDA has approved obecabtagene autoleucel, or obe-cel (AUTO1, Autolus Therapeutics), to treat relapsed or refractory adult B-cell acute lymphoblastic leukemia (ALL).

Nov 21, 2024 | mdedge.com | Victoria Stern

TOPLINE:The increase in incidence of pancreatic cancer among young Americans is largely caused by improved detection of early-stage endocrine cancer, not an increase in pancreatic adenocarcinoma. Given the stable mortality rates in this population, the increase in incidence likely reflects previously undetected cases instead of a true rise in new cases, researchers say.